vs
Anika Therapeutics, Inc.（ANIK）与GLOBUS MEDICAL INC（GMED）财务数据对比。点击上方公司名可切换其他公司
GLOBUS MEDICAL INC的季度营收约是Anika Therapeutics, Inc.的27.0倍（$826.4M vs $30.6M）。GLOBUS MEDICAL INC净利率更高（17.0% vs 1.0%，领先16.1%）。GLOBUS MEDICAL INC同比增速更快（25.7% vs 0.0%）。GLOBUS MEDICAL INC自由现金流更多（$202.4M vs $4.0M）。过去两年GLOBUS MEDICAL INC的营收复合增速更高（16.7% vs 2.7%）
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
ANIK vs GMED — 直观对比
营收规模更大
GMED
是对方的27.0倍
$30.6M
营收增速更快
GMED
高出25.7%
0.0%
净利率更高
GMED
高出16.1%
1.0%
自由现金流更多
GMED
多$198.4M
$4.0M
两年增速更快
GMED
近两年复合增速
2.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $30.6M | $826.4M |
| 净利润 | $292.0K | $140.6M |
| 毛利率 | 62.6% | 68.4% |
| 营业利润率 | 2.1% | 20.5% |
| 净利率 | 1.0% | 17.0% |
| 营收同比 | 0.0% | 25.7% |
| 净利润同比 | 101.3% | 430.4% |
| 每股收益（稀释后） | $0.02 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIKGMED
| Q4 25 | $30.6M | $826.4M | ||
| Q3 25 | $27.8M | $769.0M | ||
| Q2 25 | $28.2M | $745.3M | ||
| Q1 25 | $26.2M | $598.1M | ||
| Q4 24 | $30.6M | $657.3M | ||
| Q3 24 | $29.6M | $625.7M | ||
| Q2 24 | $30.7M | $629.7M | ||
| Q1 24 | $29.0M | $606.7M |
净利润ANIKGMED
| Q4 25 | $292.0K | $140.6M | ||
| Q3 25 | $-2.3M | $119.0M | ||
| Q2 25 | $-4.0M | $202.8M | ||
| Q1 25 | $-4.9M | $75.5M | ||
| Q4 24 | $-21.9M | $26.5M | ||
| Q3 24 | $-29.9M | $51.8M | ||
| Q2 24 | $-88.0K | $31.8M | ||
| Q1 24 | $-4.5M | $-7.1M |
毛利率ANIKGMED
| Q4 25 | 62.6% | 68.4% | ||
| Q3 25 | 56.0% | 67.2% | ||
| Q2 25 | 50.9% | 66.6% | ||
| Q1 25 | 56.1% | 67.3% | ||
| Q4 24 | 56.0% | 59.9% | ||
| Q3 24 | 65.7% | 56.8% | ||
| Q2 24 | 66.7% | 58.7% | ||
| Q1 24 | 65.4% | 60.2% |
营业利润率ANIKGMED
| Q4 25 | 2.1% | 20.5% | ||
| Q3 25 | -11.6% | 17.9% | ||
| Q2 25 | -14.8% | 10.2% | ||
| Q1 25 | -16.4% | 16.2% | ||
| Q4 24 | -2.3% | 9.2% | ||
| Q3 24 | -0.3% | 7.7% | ||
| Q2 24 | -5.9% | 7.9% | ||
| Q1 24 | -8.6% | 1.3% |
净利率ANIKGMED
| Q4 25 | 1.0% | 17.0% | ||
| Q3 25 | -8.4% | 15.5% | ||
| Q2 25 | -14.1% | 27.2% | ||
| Q1 25 | -18.6% | 12.6% | ||
| Q4 24 | -71.4% | 4.0% | ||
| Q3 24 | -101.2% | 8.3% | ||
| Q2 24 | -0.3% | 5.0% | ||
| Q1 24 | -15.6% | -1.2% |
每股收益（稀释后）ANIKGMED
| Q4 25 | $0.02 | $1.01 | ||
| Q3 25 | $-0.16 | $0.88 | ||
| Q2 25 | $-0.28 | $1.49 | ||
| Q1 25 | $-0.34 | $0.54 | ||
| Q4 24 | $-1.49 | $0.19 | ||
| Q3 24 | $-2.03 | $0.38 | ||
| Q2 24 | $0.00 | $0.23 | ||
| Q1 24 | $-0.31 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $81.2M | $557.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $143.5M | $4.6B |
| 总资产 | $190.3M | $5.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIKGMED
| Q4 25 | $81.2M | $557.2M | ||
| Q3 25 | $80.2M | $18.8M | ||
| Q2 25 | $77.1M | — | ||
| Q1 25 | $75.4M | — | ||
| Q4 24 | $79.2M | $890.1M | ||
| Q3 24 | $90.7M | $71.9M | ||
| Q2 24 | $96.6M | $82.5M | ||
| Q1 24 | $100.7M | $80.4M |
股东权益ANIKGMED
| Q4 25 | $143.5M | $4.6B | ||
| Q3 25 | $146.8M | $4.4B | ||
| Q2 25 | $147.7M | $4.3B | ||
| Q1 25 | $148.4M | $4.1B | ||
| Q4 24 | $154.0M | $4.2B | ||
| Q3 24 | $179.9M | $4.1B | ||
| Q2 24 | $210.3M | $4.0B | ||
| Q1 24 | $208.5M | $3.9B |
总资产ANIKGMED
| Q4 25 | $190.3M | $5.3B | ||
| Q3 25 | $189.4M | $5.1B | ||
| Q2 25 | $187.7M | $5.0B | ||
| Q1 25 | $190.6M | $4.7B | ||
| Q4 24 | $202.7M | $5.3B | ||
| Q3 24 | $231.4M | $5.1B | ||
| Q2 24 | $262.7M | $5.0B | ||
| Q1 24 | $263.7M | $4.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.6M | $248.6M |
| 自由现金流经营现金流 - 资本支出 | $4.0M | $202.4M |
| 自由现金流率自由现金流/营收 | 13.0% | 24.5% |
| 资本支出强度资本支出/营收 | 2.1% | 5.6% |
| 现金转化率经营现金流/净利润 | 15.88× | 1.77× |
| 过去12个月自由现金流最近4个季度 | $4.4M | $588.8M |
8季度趋势，按日历期对齐
经营现金流ANIKGMED
| Q4 25 | $4.6M | $248.6M | ||
| Q3 25 | $6.9M | $249.7M | ||
| Q2 25 | $-189.0K | $77.9M | ||
| Q1 25 | $-130.0K | $177.3M | ||
| Q4 24 | $1.6M | $210.3M | ||
| Q3 24 | $5.0M | $203.7M | ||
| Q2 24 | $-1.1M | $54.3M | ||
| Q1 24 | $-126.0K | $52.4M |
自由现金流ANIKGMED
| Q4 25 | $4.0M | $202.4M | ||
| Q3 25 | $5.0M | $213.9M | ||
| Q2 25 | $-1.7M | $31.3M | ||
| Q1 25 | $-3.0M | $141.2M | ||
| Q4 24 | $275.0K | $193.2M | ||
| Q3 24 | $3.8M | $161.7M | ||
| Q2 24 | $-4.5M | $26.5M | ||
| Q1 24 | $-1.9M | $23.8M |
自由现金流率ANIKGMED
| Q4 25 | 13.0% | 24.5% | ||
| Q3 25 | 17.9% | 27.8% | ||
| Q2 25 | -5.9% | 4.2% | ||
| Q1 25 | -11.3% | 23.6% | ||
| Q4 24 | 0.9% | 29.4% | ||
| Q3 24 | 12.9% | 25.8% | ||
| Q2 24 | -14.6% | 4.2% | ||
| Q1 24 | -6.7% | 3.9% |
资本支出强度ANIKGMED
| Q4 25 | 2.1% | 5.6% | ||
| Q3 25 | 6.8% | 4.7% | ||
| Q2 25 | 5.2% | 6.2% | ||
| Q1 25 | 10.8% | 6.0% | ||
| Q4 24 | 4.3% | 2.6% | ||
| Q3 24 | 4.1% | 6.7% | ||
| Q2 24 | 11.1% | 4.4% | ||
| Q1 24 | 6.2% | 4.7% |
现金转化率ANIKGMED
| Q4 25 | 15.88× | 1.77× | ||
| Q3 25 | — | 2.10× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | 2.35× | ||
| Q4 24 | — | 7.94× | ||
| Q3 24 | — | 3.93× | ||
| Q2 24 | — | 1.71× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIK
| OEM Channel | $17.3M | 57% |
| Commercial Channel | $13.3M | 43% |
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
